The administration of a mRNA-based vaccine encoding a portion of HER2 (VRP HER2), with or without an additional anti-HER2 targeted therapy, also demonstrated stable diseases and partial response in a phase 1 clinical trial with advanced HER2-positive BC patients (119). Here, ERBB2 is linked to breast cancer.